Citigroup Maintains Buy on DexCom, Raises Price Target to $161
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch has maintained a Buy rating on DexCom (NASDAQ:DXCM) and increased the price target from $148 to $161.
April 03, 2024 | 3:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup has reaffirmed its Buy rating on DexCom and raised the price target from $148 to $161.
The increase in the price target by a reputable analyst such as Joanne Wuensch from Citigroup is a strong positive signal for DexCom. It suggests confidence in the company's future performance and growth prospects, likely leading to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100